§ 02 · Comparison

Compare regulatory pathways side-by-side

Benchmark MAHMAH, GMPGMP, HTAHTA and pathway requirements across up to three markets.

Country A

Country B

Country C

Highlight differences

Criterion	🇸🇦Saudi Arabia 4 of 5 pathway fees confirmed	🇪🇺European Union Fees verified 12 September 2026
Authority & dossier
Fee confirmation	4 of 5 pathway fees confirmed	Fees verified 12 September 2026
Regulatory authority	SFDA	EMA
English submissions	Yes	Yes
CTD accepted	Yes	Yes
eCTD accepted	Yes	Yes
Reliance pathway	Available	Available
Reference agencies	FDA, EMA (centralised), MHRA, Health Canada +3	Not stated
Lead pathway (timeline & fees), Standard Marketing Authorisation (Full Review) · Centralised Procedure
Pathway name	Standard Marketing Authorisation (Full Review)	Centralised Procedure
Approval timeline	240-365 days	210-277 days
Headline fee and pathway	SAR 115,000, Standard Marketing Authorisation (Full Review)conditional on tax	EUR 865,200, Centralised Procedureconditional on other
Recurring charges	SAR 33,000 every 5 years, SAR 30,000 plus SAR 3,000 system fee	EUR 232,400 a year, per marketing authorisation, other applications
Local representative	Required	Required
Local manufacturing	Not required	Not required
GMP inspection	Required	Required
MAH & local presence
Local entity required	Yes	Yes
Local responsible person	Yes	Yes
RP role	A Saudi-resident Pharmacist must be designated as Responsible Person; a Pharmacovigilance Officer is required and must report to the Saudi Pharmacovigilance Centre. Saudisation (Nitaqat) requirements apply to local agent staff.	Qualified Person Responsible for Pharmacovigilance (QPPV), must reside and operate in the EU/EEA, is responsible for the establishment and maintenance of the pharmacovigilance system. A Qualified Person (QP) in the EU/EEA performs batch certification under Article 51 of Directive 2001/83/EC. Local Contact Person for pharmacovigilance required in each Member State where the product is marketed (since 2012 GVP).
Accelerated pathways
Designations available	4 designations	6 designations
Examples	Priority Review, Orphan Drug Pathway, Conditional Approval +1	Accelerated Assessment, Conditional Marketing Authorisation, Authorisation under Exceptional Circumstances +3
Post-approval lifecycle
Variations framework	Variations classified into Major, Minor, and Notification, broadly aligned with EU Type IA/IB/II framework. SFDA also accepts variation worksharing for products approved via the Verification Pathway when the SRA has approved the same change.	Commission Regulation (EC) 1234/2008 establishes four categories: Type IA (minor, Do and Tell, 12-month notification), Type IAIN (minor, immediate notification), Type IB (minor, Tell, Wait, and Do, 30-day default), Type II (major, prior approval, 60 to 90 days), and Extensions (Annex I changes, full review). Worksharing procedures consolidate variations across multiple authorisations.
Renewal cycle	Marketing authorisations valid for 5 years; renewal required 6 months before expiry. Renewal includes updated PSUR, sales data, and pharmacovigilance summary.	Initial 5-year renewal, application 9 months before expiry. After the first renewal, MA is granted for unlimited duration unless the CHMP/NCA, on justified grounds relating to pharmacovigilance, decides on one additional 5-year renewal.
Pharmacovigilance	Saudi Pharmacovigilance Centre (under SFDA). PSURs aligned with ICH E2C(R2). Mandatory ICSR reporting via the National Pharmacovigilance Centre online portal. KSA is a WHO-UMC member.	Comprehensive PV framework under Directive 2010/84/EU and Regulation (EU) 1235/2010, codified in Good Pharmacovigilance Practices (GVP). Pharmacovigilance System Master File (PSMF) required. Periodic Safety Update Reports (PSURs) on EU-harmonised birth-date list. Risk Management Plans for all new MAs and significant variations. Suspected serious ADR reporting to EudraVigilance within 15 days. Black triangle (▼) for additional monitoring of selected products.
Unlicensed access
Named Patient Supply	Available	Available
Compassionate Use	Available	Available
Emergency Import	Available	Available
Parallel Import	Not permitted	Permitted
Clinical trials
CTA approval	Required	Required
Ethics approval	Yes	Yes
CTA timeline	60-90 days	60-106 days
GCP standard	ICH-GCP	ICH E6(R3), Commission Regulation (EU) 2024/2748 transposing R3, applicable from 23 July 2025
Pricing & reimbursement
Price regulation	Regulated	Regulated
Reference pricing	Yes	Yes
HTA required	Yes	Yes
HTA body	SFDA Health Technology Assessment (HTA) Unit + Saudi Health Council HTA committee	EU HTA Coordination Group (EUnetHTA legacy); national HTA bodies (NICE, HAS, G-BA/IQWiG, AIFA, AEMPS, etc.)

Verdict colours indicate lower, moderate, or higher regulatory burden, they're not value judgements on a market.

Authority & dossier

Fee confirmation

Saudi Arabia4 of 5 pathway fees confirmed
European UnionFees verified 12 September 2026

Regulatory authority

Saudi ArabiaSFDA
European UnionEMA

English submissions

Saudi ArabiaYes
European UnionYes

CTD accepted

Saudi ArabiaYes
European UnionYes

eCTD accepted

Saudi ArabiaYes
European UnionYes

Reliance pathway

Saudi ArabiaAvailable
European UnionAvailable

Reference agencies

Saudi ArabiaFDA, EMA (centralised), MHRA, Health Canada +3
European UnionNot stated

Lead pathway (timeline & fees), Standard Marketing Authorisation (Full Review) · Centralised Procedure

Pathway name

Saudi ArabiaStandard Marketing Authorisation (Full Review)
European UnionCentralised Procedure

Approval timeline

Saudi Arabia240-365 days
European Union210-277 days

Headline fee and pathway

Saudi ArabiaSAR 115,000, Standard Marketing Authorisation (Full Review)conditional on tax
European UnionEUR 865,200, Centralised Procedureconditional on other

Recurring charges

Saudi ArabiaSAR 33,000 every 5 years, SAR 30,000 plus SAR 3,000 system fee
European UnionEUR 232,400 a year, per marketing authorisation, other applications

Local representative

Saudi ArabiaRequired
European UnionRequired

Local manufacturing

Saudi ArabiaNot required
European UnionNot required

GMP inspection

Saudi ArabiaRequired
European UnionRequired

MAH & local presence

Local entity required

Saudi ArabiaYes
European UnionYes

Local responsible person

Saudi ArabiaYes
European UnionYes

RP role

Saudi ArabiaA Saudi-resident Pharmacist must be designated as Responsible Person; a Pharmacovigilance Officer is required and must report to the Saudi Pharmacovigilance Centre. Saudisation (Nitaqat) requirements apply to local agent staff.
European UnionQualified Person Responsible for Pharmacovigilance (QPPV), must reside and operate in the EU/EEA, is responsible for the establishment and maintenance of the pharmacovigilance system. A Qualified Person (QP) in the EU/EEA performs batch certification under Article 51 of Directive 2001/83/EC. Local Contact Person for pharmacovigilance required in each Member State where the product is marketed (since 2012 GVP).

Accelerated pathways

Designations available

Saudi Arabia4 designations
European Union6 designations

Examples

Saudi ArabiaPriority Review, Orphan Drug Pathway, Conditional Approval +1
European UnionAccelerated Assessment, Conditional Marketing Authorisation, Authorisation under Exceptional Circumstances +3

Post-approval lifecycle

Variations framework

Saudi ArabiaVariations classified into Major, Minor, and Notification, broadly aligned with EU Type IA/IB/II framework. SFDA also accepts variation worksharing for products approved via the Verification Pathway when the SRA has approved the same change.
European UnionCommission Regulation (EC) 1234/2008 establishes four categories: Type IA (minor, Do and Tell, 12-month notification), Type IAIN (minor, immediate notification), Type IB (minor, Tell, Wait, and Do, 30-day default), Type II (major, prior approval, 60 to 90 days), and Extensions (Annex I changes, full review). Worksharing procedures consolidate variations across multiple authorisations.

Renewal cycle

Saudi ArabiaMarketing authorisations valid for 5 years; renewal required 6 months before expiry. Renewal includes updated PSUR, sales data, and pharmacovigilance summary.
European UnionInitial 5-year renewal, application 9 months before expiry. After the first renewal, MA is granted for unlimited duration unless the CHMP/NCA, on justified grounds relating to pharmacovigilance, decides on one additional 5-year renewal.

Pharmacovigilance

Saudi ArabiaSaudi Pharmacovigilance Centre (under SFDA). PSURs aligned with ICH E2C(R2). Mandatory ICSR reporting via the National Pharmacovigilance Centre online portal. KSA is a WHO-UMC member.
European UnionComprehensive PV framework under Directive 2010/84/EU and Regulation (EU) 1235/2010, codified in Good Pharmacovigilance Practices (GVP). Pharmacovigilance System Master File (PSMF) required. Periodic Safety Update Reports (PSURs) on EU-harmonised birth-date list. Risk Management Plans for all new MAs and significant variations. Suspected serious ADR reporting to EudraVigilance within 15 days. Black triangle (▼) for additional monitoring of selected products.

Unlicensed access

Named Patient Supply

Saudi ArabiaAvailable
European UnionAvailable

Compassionate Use

Saudi ArabiaAvailable
European UnionAvailable

Emergency Import

Saudi ArabiaAvailable
European UnionAvailable

Parallel Import

Saudi ArabiaNot permitted
European UnionPermitted

Clinical trials

CTA approval

Saudi ArabiaRequired
European UnionRequired

Ethics approval

Saudi ArabiaYes
European UnionYes

CTA timeline

Saudi Arabia60-90 days
European Union60-106 days

GCP standard

Saudi ArabiaICH-GCP
European UnionICH E6(R3), Commission Regulation (EU) 2024/2748 transposing R3, applicable from 23 July 2025

Pricing & reimbursement

Price regulation

Saudi ArabiaRegulated
European UnionRegulated

Reference pricing

Saudi ArabiaYes
European UnionYes

HTA required

Saudi ArabiaYes
European UnionYes

HTA body

Saudi ArabiaSFDA Health Technology Assessment (HTA) Unit + Saudi Health Council HTA committee
European UnionEU HTA Coordination Group (EUnetHTA legacy); national HTA bodies (NICE, HAS, G-BA/IQWiG, AIFA, AEMPS, etc.)